Epimedium(Horny Goat Weed) Extract- Lilo ʻo Icariin i Manaolana Hou i ka hakakā ʻana i ka maʻi maʻi ʻurothelial

ʻO ka carcinoma Urothelial kekahi o nā maʻi maʻi urinary maʻamau, me ka hoʻi hou ʻana o ka maʻi maʻi a me ka metastasis nā kumu prognostic nui. I ka makahiki 2023, he 168,560 mau ma'i o ka ma'i ma'i 'a'ai e 'ike 'ia ma 'Amelika Hui Pū 'ia, me ka make ma kahi o 32,590; ma kahi o 50% o kēia mau hihia he urothelial carcinoma. ʻOiai ka loaʻa ʻana o nā koho lapaʻau hou, e like me ka platinum-based chemotherapy a me PD1 antibody-based immunotherapy, ʻoi aku ma mua o ka hapalua o nā maʻi maʻi carcinoma urothelial ʻaʻole i pane i kēia mau lapaʻau. No laila, he mea koʻikoʻi e noiʻi i nā mea lapaʻau hou e hoʻomaikaʻi i ka prognosis o nā maʻi maʻi carcinoma urothelial.

Icariin(ICA), ka mea hana nui i loko o Epimedium, he tonic, aphrodisiac, a anti-rheumatic lāʻau lapaʻau Kina. Ke hoʻokomo ʻia, ua hoʻololi ʻia ka ICA i ka icartin (ICT), a laila e hoʻokō i kāna mau hopena. He nui nā hana olaola o ICA, me ka hoʻoponopono ʻana i ka palekana adaptive, loaʻa nā waiwai antioxidant, a me ka pale ʻana i ka piʻi ʻana o ka tumor. I ka makahiki 2022, ua ʻae ʻia nā capsules Icaritin me ICT ma ke ʻano he kumu nui e ka China National Medical Products Administration (NMPA) no ka mālama mua ʻana i ka maʻi maʻi hepatocellular inoperable. Eia kekahi, ua hōʻike ʻia ka mana nui i ka hoʻolōʻihi ʻana i ke ola holoʻokoʻa o nā maʻi me ka maʻi maʻi hepatocellular kiʻekiʻe. ʻAʻole pepehi wale ʻo ICT i nā maʻi maʻi ma o ka hoʻoulu ʻana i ka apoptosis a me ka autophagy, akā hoʻoponopono pū i ka microenvironment immune a hoʻoikaika i ka pane ʻana i ka anti-tumor. Eia nō naʻe, ʻaʻole maopopo loa ka hana kikoʻī e hoʻoponopono ai ʻo ICT i ka TME, ʻoi aku hoʻi i ka carcinoma urothelial.

I kēia mau lā, ua hoʻopuka nā mea noiʻi mai ka 'Oihana Urology, Huashan Hospital, Fudan University i kahi ʻatikala i kapa ʻia ʻo "Icaritin inhibits the progression of urothelial cancer by suppressing PADI2-mediated neutrophil infiltration and neutrophil extracellular trap formation" ma ka puke pai Acta Pharm Sin B. kēlāicariinua hoʻemi nui ʻia ka laha a me ka holomua ʻana i ka neutrophil infiltration a me ka synthesis NET, e hōʻike ana i ka ICT he mea hou NETs inhibitor a me kahi lāʻau hou no ka carcinoma urothelial.

ʻO ka hoʻi hou a me ka metastasis ke kumu nui o ka make ma ka carcinoma urothelial. I loko o ka microenvironment tumor, nā molekala hoʻoponopono maikaʻi ʻole a me nā subtypes cell immune he nui e hoʻopau i ka immunity antitumor. ʻO ka microenvironment inflammatory, pili me nā neutrophils a me nā neutrophil extracellular traps (NETs), hoʻolaha i ka metastasis tumor. Eia nō naʻe, ʻaʻohe lāʻau lapaʻau i kēia manawa e kāohi pono i nā neutrophils a me nā NETs.

Ma kēia haʻawina, hōʻike nā mea noiʻi no ka manawa mua i kēlāicariin, he lāʻau lapaʻau mua no ka maʻi maʻi hepatocellular kiʻekiʻe a hiki ʻole ke hoʻōla, hiki ke hōʻemi i nā NET i hana ʻia e ka NETosis suicidal a pale i ka infiltration neutrophil i ka microenvironment tumor. Mechanistically, hoʻopaʻa ʻo ICT i ka hōʻike ʻana o PADI2 i loko o nā neutrophils, a laila e kāohi ana i ka PADI2-mediated histone citrullination. Eia hou, ho'ōki ka ICT i ka hana ROS, keʻakeʻa i ke ala hōʻailona MAPK, a hoʻopau i ka metastasis tumor i hoʻokomoʻia e NET.

I ka manawa like, hoʻoneʻe ʻo ICT i ka tumo PADI2-mediated histone citrullination, a laila ke kāohi nei i ka transcription o nā genes recruitment neutrophil e like me GM-CSF a me IL-6. Ma ka huli ʻana, hoʻohaʻahaʻa i ka ʻōlelo IL-6 e hana i kahi loop pane hoʻoponopono ma o ka JAK2/STAT3/IL-6 axis. Ma o kahi noiʻi retrospective o nā laʻana lapaʻau, ua ʻike nā mea noiʻi i kahi pilina ma waena o nā neutrophils, NETs, ​​​​UCa prognosis a me ka pakele ʻana. Loaʻa paha ka hopena synergistic i hui pū ʻia me ka ICT me nā mea hoʻopaʻa hoʻopaʻa pale.

I ka hōʻuluʻulu ʻana, ua ʻike kēia haʻawinaicariinUa ho'emi nui 'ia ka laha a me ka holomua 'ana i ka neutrophil infiltration a me ka NET synthesis, a ho'okani 'o neutrophils a me NETs i ka hana inhibitory i ka ma'i microenvironment immune o ka po'e ma'i me ka carcinoma urothelial. Eia kekahi, ʻo ka ICT i hui pū ʻia me ka anti-PD1 immunotherapy he hopena synergistic, e hōʻike ana i kahi hoʻolālā lapaʻau kūpono no nā poʻe maʻi me ka carcinoma urothelial.